EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells

BACKGROUND: BRAF inhibitor (BRAF-I) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms behind BRAF-I responsiveness and acquired resistance is therefore an important iss...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurenzana, Anna, Margheri, Francesca, Biagioni, Alessio, Chillà, Anastasia, Pimpinelli, Nicola, Ruzzolini, Jessica, Peppicelli, Silvia, Andreucci, Elena, Calorini, Lido, Serratì, Simona, Del Rosso, Mario, Fibbi, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355443/
https://www.ncbi.nlm.nih.gov/pubmed/30611716
http://dx.doi.org/10.1016/j.ebiom.2018.12.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355443/
https://www.ncbi.nlm.nih.gov/pubmed/30611716
http://dx.doi.org/10.1016/j.ebiom.2018.12.024

Ejemplares similares